Angiotensin-converting enzyme inhibitors and angiotensin receptor blockers in renal transplantation between 1990 and 2002 in Spain

Ángel Alonso Hernández¹, Francesc Moreso², Beatrix Bayés³, Ricardo Lauzurica³, Dámaso Sánz-Guajardo⁴, Ernesto Gómez-Huertas⁵, Porfirio Pereira⁶, Javier Paul⁷, Josep Crespo⁸, Juan J. Amenábar⁹, Juan Oliver¹ and Daniel Serón²

¹Nephrology Department, Hospital Universitario de A Coruña, La Coruña, Spain, ²Nephrology Department, Hospital Universitario Vall d’Hebrón, Barcelona, Spain, ³Nephrology Department, Hospital Germans Trias i Pujol, Barcelona, Spain, ⁴Nephrology Department, Hospital Universitario Puerta de Hierro, Madrid, Spain, ⁵Nephrology Department, Hospital Central de Asturias, Oviedo, Spain, ⁶Nephrology Department, Hospital Virgen del Rocío, Sevilla, Spain, ⁷Nephrology Department, Hospital Miguel Servet, Zaragoza, Spain, ⁸Nephrology Department, Hospital Peset, Valencia, Spain and ⁹Nephrology Department, Hospital de Cruces, Barakaldo, Spain

Correspondence and offprint request to: Angel Alonso Hernández; E-mail: angel.alonso.hernandez@sergas.es

Abstract

Background. Angiotensin-converting enzyme inhibitors (ACEI) and angiotensin II type 1 receptor blockers (ARB) decrease cardiovascular mortality and slow the progression of renal disease in non-transplant patients, but their impact on kidney transplant outcome has not been well established.

Methods. Patients receiving a renal allograft in Spain in 1990, 1994, 1998 and 2002 were considered for the present study. Only adult (≥18 years) recipients of a single kidney transplant functioning at the end of the first year were considered. A total of 4842 patients with clinical data about ACEI/ARB therapy were included.

Results. During the initial 2 years after transplant, ACEI/ARB were less frequently used in the 1990 and 1994 cohorts than in 1998 and 2002 (15.1%, 24.6%, 33.5% and 45.1%, respectively; \( P < 0.001 \)). During the first year, a total of 1063 patients (22.8%) received ACEI/ARB treatment, and graft survival (50.0% for treated patients and 51.4% for untreated, \( P = \text{ns} \)), death-censored graft survival (60.6% versus 63.5%, \( P = \text{ns} \)) and patient survival (68.8% versus 66.6%, \( P = \text{ns} \)) were not different.

Conclusions. The use of ACEI/ARB during the initial 2 years after transplantation was associated with a better graft survival, but this effect was only observed in the 2002 cohort.

Keywords: angiotensin-converting enzyme inhibitors; angiotensin receptor blockers; graft survival; renal transplantation

Introduction

Angiotensin-converting enzyme inhibitors (ACEI) and angiotensin II type 1 receptor blockers (ARB) decrease cardiovascular mortality, reduce proteinuria and delay progression to end-stage renal failure in native kidneys [1–3]. Trials using ACEI or ARB in renal transplant recipients to study their potential benefit on graft function are limited, and until now there has been only one systematic review [4]. Taking into consideration the better understanding of the mechanisms leading to chronic renal allograft dysfunction and the better understanding of the systemic and intrarenal effects of ACEI/ARB [5], it has been suggested that these medications may also prolong renal allograft survival [6–9]. However, these advantages should be balanced with an increased prevalence of side effects such as anaemia, decreased glomerular filtration rate and hyperkalaemia [4, 10] that may limit the effectiveness of these drugs in the kidney transplant population.

In the present study, we evaluate the association between ACEI/ARB treatment and graft and patient outcome in patients transplanted in 1990, 1994, 1998 and 2002 in Spain.
Materials and methods

Study design

Patients receiving a renal allograft in Spain in 1990, 1994, 1998 and 2002 were considered for the present study. All Spanish adult transplant centres were invited to participate, and only adult patients (≥18 years) receiving a single kidney transplant that was functioning at the end of the first year were considered. Patients receiving multi-organ or double transplants were excluded. Last follow-up was on 31 December 2005.

Clinical variables

The following variables were evaluated at the time of surgery: source of the organ (living or deceased donor), donation before or after cardiac death, cause of donor death (trauma, stroke or others), age and gender of the donor and the recipient, height and weight of the recipient, presence of hepatitis B surface antigen and hepatitis C virus antibodies in the donor and the recipient, aetiology of end-stage renal disease, time on dialysis, last panel reactive antibodies (PRA), number of human leukocyte antigen (HLA) mismatches and cold ischaemia and re-anastomosis times.

After surgery, the presence of delayed graft function and acute rejection were recorded. Immunosuppressive treatment at 1 year was described on an intention-to-treat basis and classified into four major groups: (i) cyclosporine-based not associated with mycophenolate mofetil, (ii) cyclosporine-based associated with mycophenolate mofetil, (iii) tacrolimus-based treatment and (iv) other treatments.

At 3 months and yearly thereafter, serum creatinine, 24 h proteinuria, serum fasting glucose and serum cholesterol and triglycerides were recorded. Treatment with antihypertensive drugs including ACEI or ARB was also recorded.

Definition of variables

Total number of HLA mismatches was calculated as the addition of the number of mismatches in the A, B and DR loci. Delayed graft function was defined as haemodialysis requirements during the first week after surgery once accelerated or hyperacute rejection, vascular complications and urinary tract obstruction were ruled out. The diagnosis of acute rejection was defined at each centre based on clinical and/or histological data.

Statistics

Descriptive results are expressed as frequencies and percentages for categorical variables: median, 25th and 75th percentiles for skewed continuous variables and mean ± standard deviation for normally distributed continuous variables. These variables were compared in ACEI/ARB users.

Table 1. Treatment with ACEI/ARB by year of transplantation

| ACEI/ARB                  | 1990 N (%) | 1994 N (%) | 1998 N (%) | 2002 N (%) | Overall N (%) | P-value<sup>c</sup> |
|---------------------------|------------|------------|------------|------------|---------------|---------------------|
| At 3 months               | 49 (6.1)   | 64 (5.9)   | 114 (7.6)  | 240 (18.8) | 467 (10.0)    | <0.001              |
| At 1 year                 | 78 (9.7)   | 148 (13.7) | 324 (21.5) | 447 (34.9) | 997 (21.4)    | <0.001              |
| At 2 year                 | 101 (12.9) | 225 (21.7) | 451 (31.0) | 529 (43.3) | 1306 (29.0)   | <0.001              |

During first year<sup>a</sup>

|             | 86 (10.7) | 164 (15.2) | 341 (22.7) | 472 (36.9) | 1063 (22.8) | <0.001              |
|             | 122 (15.1) | 266 (24.6) | 505 (33.5) | 579 (45.1) | 1472 (31.4) | <0.001              |

During second year<sup>b</sup>

Table 2. Baseline characteristics into ACEI/ARB use during the first year

| Characteristics                                      | No ACEI/ARB N (%) | ACEI/ARB N (%) | P-value |
|------------------------------------------------------|-------------------|----------------|---------|
| Donor age (year)                                     |                   |                |         |
| 41.6 (16.8)                                          | 43.1 (17.0)       | 0.023          |
| Donor female gender                                  |                   |                |         |
| 1287 (35.7)                                          | 364 (34.3)        | 0.387          |
| Patient age (year), mean (SD)                        |                   |                |         |
| 46.2 (13.3)                                          | 47.6 (12.8)       | 0.010          |
| Patient female gender                                |                   |                |         |
| 1389 (38.5)                                          | 334 (31.5)        | <0.001         |
| Diabetes at transplantation                          |                   |                |         |
| 156 (4.6)                                            | 97 (9.3%)         | <0.001         |
| Hepatitis C virus positive                            |                   |                |         |
| 502 (15.1)                                           | 104 (10.3)        | <0.001         |
| Weight (kg), mean (SD)                               |                   |                |         |
| 65.8 (12)                                            | 68.5 (12.4)       | <0.001         |
| HLA mismatches                                       |                   |                |         |
| 0                                                    | 1249 (35.7)       | 307 (29.5)     | <0.001  |
| 1                                                    | 1977 (56.6)       | 595 (57.1)     | <0.001  |
| 2                                                    | 270 (7.7)         | 139 (13.4)     | 0.001   |
| Immunosuppression                                    |                   |                |         |
| Cyclosporine without mycophenolate mofetil           | 1834 (51.1)       | 342 (32.2)     | <0.001  |
| Cyclosporine with mycophenolate mofetil              | 813 (22.6)        | 266 (25)       | <0.001  |
| Tacrolimus                                           | 639 (17.8)        | 332 (31.2)     | <0.001  |
| Other treatments                                     | 304 (8.5)         | 123 (11.6)     | <0.001  |
| Delayed graft function                               | 1027 (30.2)       | 318 (32.1)     | 0.254   |
| Acute rejection                                      | 1053 (29.2)       | 264 (24.8)     | 0.0005  |
| New onset diabetes after transplantation             | 193 (5.6)         | 57 (5.4)       | <0.001  |
| Impaired glucose tolerance after transplant          | 624 (18)          | 219 (20.9)     |         |
| Creatinine 1 year (mg/dl), mean (SD)                 | 1.6 (0.7)         | 1.7 (0.7)      | 0.014   |
| Proteinuria 1 year (g/day), mean (SD)                | 0.3 (0.8)         | 0.4 (1.0)      | <0.001  |
| Cholesterol 1 year (mg/dl), mean (SD)                | 220.9 (45.9)      | 213.7 (45.8)   | 0.296   |
| Triglycerides 1 year (mg/dl), mean (SD)              | 148.4 (71.5)      | 152.7 (74.6)   | <0.001  |

<sup>a</sup>ACEI/ARB in visit at 3 months and/or 1 year.
<sup>b</sup>ACEI/ARB in visit at 3 months and/or 1 and/or 2 years.
<sup>c</sup>Chi-square test.
ACE inhibitors and ARB in renal transplantation

Table 3. Baseline characteristics into ACEI/ARB use during 2nd year

| Characteristics                             | no ACEI/ARB N (%) | ACEI/ARB N (%) | P-value |
|---------------------------------------------|-------------------|----------------|---------|
| Donor age (year), mean (SD)                 | 41.3 (16.9)       | 43.4 (16.8)    | <0.001  |
| Donor female gender                         | 1146 (35.7)       | 508 (34.5)     | 0.430   |
| Patient age (year), mean (SD)               | 46.1 (13.4)       | 47.4 (12.7)    | 0.006   |
| Patient female gender                       | 1281 (39.9)       | 444 (30.2)     | <0.001  |
| Diabetes at transplantation                | 1367 (4.4)        | 1197 (8.3)     | <0.001  |
| Hepatitis C virus                           | 459 (15.6)        | 149 (10.6)     | <0.001  |
| Weight (kg), mean (SD)                      | 65.4 (12.0)       | 68.5 (12.4)    | <0.001  |
| HLA mismatches                              |                   |                |         |
| 0                                           | 1123 (36.2)       | 440 (30.5)     | <0.001  |
| 1                                           | 1764 (56.2)       | 829 (57.4)     | <0.001  |
| 2                                           | 236 (7.6)         | 174 (12.1)     | <0.001  |
| Immunosuppression                           |                   |                |         |
| CSA without MMF                             | 1671 (52.3)       | 513 (34.9)     | <0.001  |
| CSA with MMF                                | 701 (21.9)        | 380 (25.8)     | <0.001  |
| Tacrolimus based                            | 554 (17.3)        | 420 (28.6)     | <0.001  |
| Other treatments                            | 270 (8.4)         | 158 (10.7)     | <0.001  |
| Delayed graft function                      | 916 (30.2)        | 437 (31.8)     | 0.264   |
| Acute rejection                             | 940 (29.3)        | 380 (25.8)     | 0.014   |
| New onset diabetes after transplantation    | 161 (5.3)         | 89 (6.1)       | <0.001  |
| Impaired glucose tolerance after transplant | 549 (17.9)        | 294 (20.2)     | <0.001  |
| Creatinine 1 year (mg/dl), mean (SD)        | 1.6 (0.7)         | 1.7 (0.7)      | 0.004   |
| Proteinuria 1 year (g/day), mean (SD)       | 0.3 (0.8)         | 0.4 (0.9)      | <0.001  |
| Cholesterol 1 year (mg/dl), mean (SD)       | 221 (46.0)        | 214.7 (45.6)   | 0.959   |
| Triglycerides 1 year (mg/dl), mean (SD)     | 149 (7.2)         | 150.0 (7.2)    | 0.001   |

Survival and ACEI/ARB treatment during the first year after transplant

The proportion of recipients receiving ACEI/ARB treatment during the first year after transplantation increased from 10.7% in the 1990 cohort to 39.9% in the 2002 cohort. During the first year of follow-up, a total of 1063 patients (22.8%) were treated with ACEI/ARB, and graft survival was 51.4% for patients not receiving ACEI/ARB and 50.5% for treated patients (P = ns). Cox regression analysis adjusting for the year of transplant confirmed that there was no association between ACEI/ARB use and graft survival. However, there was a significant interaction between year of transplant and ACEI/ARB treatment (P = 0.046). For this reason, the effect of ACEI/ARB treatment on graft survival was analysed in each cohort. A significant difference was only observed in the 1994 cohort in the univariate analysis (relative risk (RR): 0.74 and 95% confidence interval (CI): 0.56–0.97; P = 0.03), but multivariate Cox regression analysis including the propensity score for ACEI/ARB treatment did not confirm the association between ACEI/ARB treatment and graft survival in the 1994 cohort.

Death-censored graft survival was 63.5% for untreated patients and 60.6% for treated patients (P = ns). Similarly, patient survival was 66.6% and 68.8%, respectively (P = ns).

Survival and ACEI/ARB during the initial 2 years after transplant

The proportion of recipients receiving ACEI/ARB treatment during the initial 2 years after transplantation increased from 15.1% in the 1990 cohort to 45.1% in the 2002 cohort. During the initial 2 years after transplantation, 1472 patients (31.4%) received treatment with ACEI/ARB,
and graft survival was 50.9% for patients not treated with ACEI/ARB and 54.4% for patients treated with ACEI/ARB ($P = 0.063$). Cox regression analysis adjusting for the year of transplant showed that there was no association between ACEI/ARB use and graft survival. However, there was a significant interaction between year of transplant and ACEI/ARB treatment ($P = 0.037$). For this reason, the effect of ACEI/ARB on graft survival was further analysed in each cohort of patients. A lower risk of graft failure was observed in patients transplanted in 2002 (relative risk: 0.46 and 95% CI of 0.23–0.88; $P = 0.020$). Multivariate Cox regression analysis including the propensity score for ACEI/ARB treatment confirmed the association between ACEI/ARB treatment and graft survival in the 2002 cohort (Table 4).

| Variable                        | RR    | IC 95%     | $P$-value |
|---------------------------------|-------|------------|-----------|
| Hepatitis C virus positive      | 2.50  | 1.21–5.57  | 0.0252    |
| Surgical complications          | 2.32  | 1.11–4.87  | 0.0247    |
| Delayed graft function          | 1.92  | 1.02–3.60  | 0.0412    |
| ACEI/ARB during second year     | 0.36  | 0.17–0.75  | 0.0069    |
| Creatinine at 3 months          | 2.33  | 1.47–3.68  | 0.0003    |
| Creatinine increase from 0 to 3 months | 4.17  | 2.80–6.20  | <0.0001   |

Death-censored graft survival was 63.1% for untreated patients and 63.8% for treated patients ($P = ns$). Similarly, patient survival was 66.5% and 68.1%, respectively ($P = ns$).

**Discussion**

A significant proportion of kidney transplant recipients have a reduced glomerular filtration rate and, accordingly, an increased cardiovascular risk and increased probability for renal function deterioration [11]. Different strategies have been employed to slow the decline of renal function including the adjustment of immunosuppression, treatment of hypertension or treatment of lipid abnormalities [12,13]. The proven efficacy of treatment with ACEI/ARB on the progression of native renal disease suggested that a similar benefit may be observed in transplanted patients. Possible renoprotective mechanisms of these medications include a decrease in the systemic and intraglomerular blood pressure, prevention of renal scarring, inhibition of AT II-mediated glomerulosclerosis and reduction of proteinuria [5,14,15]. These expectations were sustained by a recent report [7] showing that treatment with ACEI/ARB in 2,031 renal transplants performed between 1990 and 2003 in an Austrian centre was associated with a significant improvement of long-term graft and patient survival. However, the retrospective study conducted by Opelz et al. [9] including 17 207 kidney recipients and 1744 heart transplants failed to demonstrate an association between ACEI/ARB treatment and transplant outcome. Recently, Amara et al. [17] showed that the rate of decline of renal function in patients with chronic allograft nephropathy and severe renal impairment was not adversely affected by 1-year lisinopril treatment, but there was no amelioration of renal function deterioration rate.

In our study, we analysed patients treated with ACEI/ARB during the first year or the first 2 years of follow-up in comparison to patients not receiving renin–angiotensin blockade. Analysis of patient and graft survival in patients treated with ACEI/ARB during the first year did not show any difference between groups. The proportion of recipients receiving ACEI/ARB during the first year after transplantation increased from 10.7% in the 1990 cohort to 39.9% in the 2002 cohort, showing an important time-dependent modification of the indication criteria for ACEI/ARB in transplanted patients.

The evaluation of patients treated with ACEI/ARB during the initial two years yielded similar results. There were no differences in graft survival between treated or not treated patients in the analysis of all cohorts, but since there was an interaction between treatment and year of transplant, we further analysed each cohort separately. This analysis showed a reduced risk of graft failure for treated patients transplanted in 2002. Multivariate Cox regression analysis including a propensity score confirmed this finding. However, it is important to notice that there are limitations in this observational, retrospective study. The association between ACEI/ARB and outcome may be spurious, since multiple comparisons were done and the association between treatment and outcome was relatively weak. The advantage that in the 2002 cohort treated and untreated patients were distributed in a similar proportion may be overcome by the shorter follow-up of these patients. Thus, the potential benefit of ACEI/ARB on outcome is a question that remains open and that can only be answered by means of prospective randomized clinical trials.

**Acknowledgements.** We are grateful to Jordi Curto for statistical advice.

**Conflict of interest statement.** None declared.

**References**

1. Brenner BM, Cooper ME, de Zeeuw D et al. Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy. *N Engl J Med* 2001; 345: 861–869
2. Lewis EJ, Hunsicker LG, Bain RP et al. The effect of angiotensin-converting enzyme-inhibition on diabetic nephropathy. *N Engl J Med* 1993; 329: 1456–1462
3. Cohen DL, Townsend RR. Is there value to adding ARB to ACE inhibitors in the management of CKD?. *J Am Soc Nephrol* 2009; 7: 2350–2360
4. El-Agroudy AE, Hassan NA, Foda MA et al. Effect of angiotensin II receptor blocker on plasma levels of TGF-beta 1 and interstitial fibrosis in hypertensive kidney transplant patients. *Am J Nephrol* 2003; 23: 300–306
5. Artz MA, Hilbrands LB, Borm G et al. Blockade of the renin–angiotensin system increases graft survival in patients with chron-...
ic allograft nephropathy. *Nephrol Dial Transplant* 2004; 19: 2852–2857
7. Heinze G, Mitterbauer C, Regele H *et al*. Angiotensin-converting enzyme inhibitor or angiotensin II type 1 receptor antagonist therapy is associated with prolonged patient and graft survival after renal transplantation. *J Am Soc Nephrol* 2006; 17: 889–899
8. Zaltzman JS, Nash M, Chiu R *et al*. The benefits of renin–angiotensin blockade in renal transplant recipients with biopsy-proven allograft nephropathy. *Nephrol Dial Transplant* 2004; 19: 940–944
9. Opelz G, Zeier M, Laux G *et al*. No improvement of patient or graft survival in transplant recipients treated with angiotensin-converting enzyme inhibitors or angiotensin II type 1 receptor blockers: a collaborative transplant study report. *J Am Soc Nephrol* 2006; 17: 3257–3262
10. Palmer BF. Managing hyperkalemia caused by inhibitors of the renin–angiotensin–aldosterone system. *N Engl J Med* 2004; 351: 585–592
11. Karthikeyan V, Karpinski J, Nair RC *et al*. The burden of chronic kidney disease in renal transplant recipients. *Am J Transplant* 2004; 4: 262–269
12. Wormer KL, Vella JP, Sayegh MH *et al*. Chronic allograft dysfunction: mechanisms and new approaches to therapy. *Semin Nephrol* 2000; 20: 126–147
13. Seron D, Moreso F, Grinyo JM. Prevention and management of late renal allograft dysfunction. *J Nephrol* 2001; 14: 71–79
14. Stigant CE, Cohen J, Vivera BS *et al*. ACE inhibitors and angiotensin II antagonists in renal transplantation: an analysis of safety and efficacy. *Am J Kidney Dis* 2000; 35: 58–63
15. Lin J, Valeri A, Markowitz GS *et al*. Angiotensin-converting enzyme inhibition in chronic allograft nephropathy. *Transplantation* 2002; 73: 783–788
16. Tutone VK, Mark PB, Stewart GA *et al*. Hypertension, antihypertensive agents and outcomes following renal transplantation. *Clin Transplant* 2005; 19: 181–192
17. Amara AB, Sharma A, Alexander JL *et al*. Randomized controlled trial: lisinopril reduces proteinuria, ammonia, and renal polypeptide tubular catabolism in patients with chronic allograft nephropathy. *Transplantation* 2010; 89: 104–114

*Received for publication: 18.12.09. Accepted in revised form: 29.3.10*